Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 16,569 shares at $1.86 ($31K) on 2015-04-06, disclosed to the SEC on 2015-04-08.
Scheduled sale ($31k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.86 | 800 | $1K | 4.8% |
| 2 | $1.87 | 5,300 | $10K | 31.8% |
| 3 | $1.87 | 800 | $1K | 4.8% |
| 4 | $1.88 | 1,900 | $4K | 11.4% |
| 5 | $1.88 | 769 | $1K | 4.6% |
| 6 | $1.89 | 1,400 |
| $3K |
| 8.5% |
| 7 | $1.89 | 2,000 | $4K | 12.1% |
| 8 | $1.90 | 1,600 | $3K | 9.7% |
| 9 | $1.90 | 100 | $190 | 0.6% |
| 10 | $1.91 | 100 | $191 | 0.6% |
| 11 | $1.91 | 1,400 | $3K | 8.6% |
| 12 | $1.92 | 100 | $192 | 0.6% |
| 13 | $1.92 | 300 | $576 | 1.8% |
| Total | $1.88 avg | 16,569 | $31K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |